This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
by Sweta Killa
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
5 Small-Cap ETFs at the Forefront of the 2021 Market Rally
by Sweta Killa
We have presented five ETFs that are easily crushing the Russell 2000 Index this year and are likely to continue their strong performance at least in the near term.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
5 Small-Cap Sector ETFs Beating the Russell 2000
by Sweta Killa
We have presented five ETFs that have easily crushed the Russell 2000 Index over the past three months.
Biotech ETF (SBIO) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Can Small-Cap ETFs Keep Up the Winning Trend in November?
by Sanghamitra Saha
The month of October was downbeat for Wall Street due to election uncertainty, failed stimulus talks, subdued tech earnings and rising coronavirus cases on the global front.
5 Sector ETFs That Showed Strength Despite the Worst October
by Sweta Killa
Wall Street registered its first back-to-back monthly loss of this year, with Dow Jones closing out the worst month since March.
Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal
by Sweta Killa
These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.
New GERM ETF Launched to Tap the Growing Biotech Sector
by Sweta Killa
GERM invests in the hottest emerging biotechnology trends.
Don't "Bet Against the American Economy:" ETF Areas to Win
by Sanghamitra Saha
Fed Chair Powell expressed optimism about the U.S. economic recovery over the long term. These ETF areas should benefit ahead.
Follow Warren Buffett With 5 ETF Strategies & Tackle COVID-19
by Sanghamitra Saha
Follow Warren Buffett???s latest COVID-19-fighting tips with these ETF strategies.
The Zacks Analyst Blog Highlights: SGDJ, PKB, SBIO and TAN
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SGDJ, PKB, SBIO and TAN
Bet on "American Magic" With 4 Solid Small-Cap Sector ETFs
by Sanghamitra Saha
These small-cap sector ETFs have put a great show in the past month and are likely to fare better in the post-lockdown period.
First-Mover Pandemic Disease Fight ETF On The Way
by Sweta Killa
Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners
by Sanghamitra Saha
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.
4 Sector ETFs That Beat the Market in Q4
by Sanghamitra Saha
While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
Will Biotech ETFs Excel in Election Year Post a Surge in 2019?
by Sanghamitra Saha
Can biotech ETFs repeat its success story of 2019 in the election year of 2020?
5 ETF Areas Up At Least 45% in 2019
by Sanghamitra Saha
These ETF areas crushed the S&P 500 in 2019.
Beyond Biotech, 5 ETFs Up At Least 10% in Q4
by Sanghamitra Saha
Apart from biotech, these ETFs are seeing solid momentum in the ongoing quarter.
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
A Guide to Biotech ETF Investing
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.